Molecular docking studies of benzimidazopyrimidine and coumarin substituted benzimidazopyrimidine derivatives: As potential human Aurora A kinase inhibitors.

Protein kinases are important drug targets in human cancers, inflammation and metabolic diseases. Docking studies was performed for all the benzimidazopyrimidine and coumarin substituted benzimidazopyridimine derivatives with human Aurora A kinase target (3FDN) employing flexible ligand docking approach by using AutoDock 4.2. All the compounds were found to have minimum binding energy ranging from -6.26 to -9.29 kJ/mol. Among the molecules tested for docking study, 10-(6-Bromo-2-oxo- 2H-chromen-4-ylmethyl)-2-isopropyl-10H-benzo[4,5]imidazo[1,2-a]pyrimidin-4-one (2k) showed minimum binding energy (-9.29 kJ/mol) with ligand efficiency of -0.31. All the ligands were docked deeply within the binding pocket region of 3FDN showing hydrogen bonds with Ala 213 and Asn 261. The docking study results showed that these derivatives are excellent inhibitor of human Aurora A kinase target; and also all these docked compounds have good inhibition constant, vdW + Hbond + desolv energy with best RMSD value

Addition of NOCl to cyclic vinylsilanes: An unexpected reversal of regiochemistry

NOCl adds to cyclic vinylsilanes in a syn manner with NO+ bonding to the β-carbon and Cl- to the α-carbon, which is a reversal of the regiochemistry expected from the β-silicon effect. The adducts dimerize to a single diastereomer containing enantiomeric pairs and/or give secondary products on further reaction. © 2001 Elsevier Science Ltd

ChemInform Abstract: Addition of NOCl to Cyclic Vinylsilanes: An Unexpected Reversal of Regiochemistry.

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option

(2,4-dichlorophenoxy)acetohydrazide

The title compound, C8H8Cl2N2O2, is an intermediate compound in the synthesis of one of the important 1,2,4-triazoles that possess diverse pharmacological activities